Compare Incyte Corporation (INCY) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Noble Corporation plc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Noble Corporation plc trades at $42.36 (market cap $6.73B). The key difference: Incyte Corporation is far larger — about 3.4× Noble Corporation plc's market cap, and Noble Corporation plc pays a 4.74% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Noble Corporation plc for 26 Days on average.
| INCY | NE | |
|---|---|---|
Market Cap | $22.85B | $6.73B |
Volume | 1,927,029 | 1,027,635 |
Sector | Health | Energy |
52-Week High | $129.93 | $54.37 |
52-Week Low | $83.80 | $26.70 |
Typical Hold Time | 33 Days | 26 Days |
Enterprise Value | $18.35B | $8.16B |
Dividend Yield | — | 4.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Noble Corporation (NE) trades at $42.36, up 3.39% on the day. The stock shows mixed signals with a bearish technical trend but positive analyst sentiment, evidenced by a consensus price target of $52.00. Recent earnings have been volatile, with a beat in Q1 2026 but misses in Q4 2025 and Q2 2026. Financially, the company reported 2025 revenue of $3.29 billion and net income of $216.72 million, though 2026 projections indicate a decline in both revenue and profitability. A key recent development is the securing of a long-term drilling contract in Ghana, extending utilization into 2027.
The outlook for NE is cautiously optimistic, supported by new contracts and a positive analyst consensus, but tempered by earnings volatility and a bearish technical setup. Investment opportunities lie in the potential upside to the price target and stable cash flows, while risks include inconsistent earnings performance and ongoing legal investigations noted in recent news. Investors should weigh contract wins against fundamental softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
